Stock News

Gilead licensing three pre-clinical programs from Novartis
Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis
Gilead's Chief Scientific Officer to leave next month
Gilead Sciences Announces Changes to Senior Leadership Team
Gilead Sciences’ Chief Scientific Officer John McHutchison to Leave the Company
Gilead Sciences to Release Second Quarter 2019 Financial Results on Tuesday, July 30, 2019
Doctor Who Sold $12 Billion Drug Firm Eyes Biotech Property

As seen on...